Ablexis Reports 33 AlivaMab(R) Mouse-Derived Human Antibodies Now in Clinical Development, Further Validating AlivaMab Mouse Transgenic Platform
-
Stocks mixed and oil rises as US, Iran call end to latest attacks
-
EU, China trade tensions loom over minister visit
-
For sale on Facebook: monkeys, rhino horn and dead pangolins
-
Israelis, Palestinians torn over sacred shrine in city of Hebron
-
In Sudan's Kordofan, a key city reels as paramilitary offensive looms
-
Scheffler to face Hovland in Monday playoff for PGA Travelers title
-
Ryu Hae-ran wins Women's PGA Championship
-
'Burnt out' Stokes leaves England facing tricky questions
-
Germany must win to defy World Cup doubters, says Nagelsmann
-
Critical rescue window closing in Venezuela as quake death toll nears 1,500
-
South Korea's Ryu Hae-ran wins Women's PGA Championship
-
Canada's Marsch praises history-making World Cup 'heroes'
-
Brazil strike confident tone ahead of Japan World Cup clash
-
Co-hosts Canada beat South Africa to reach World Cup last 16 as knockouts begin
-
Israel detonates tunnel, strikes south Lebanon
-
Putin acknowledges fuel shortages after Ukraine strikes
-
Moriyasu praises 'united' Japan on eve of Brazil World Cup clash
-
Canada reach World Cup last 16 as late strike sinks South Africa
-
Looting, theft in Venezuela's earthquake zone add to tragedy
-
Perry stars as Australia knock India out of World Cup
-
Venezuela quakes kill 1,450, time running out to find survivors
-
Stokes 'content' after extraordinary England exit
-
West Indies beat Sri Lanka in first Test
-
Europe swelters as heatwave moves east
-
Asia's World Cup falls apart with just two teams remaining
-
Stokes announces shock England exit as New Zealand eye series win
-
Bromell upsets Lyles, Duplantis shines at Paris Diamond League
-
CAF president Motsepe hails African World Cup successes
-
Man Utd reveal Ugarte knee injury in Uruguay World Cup defeat
-
South Korea coach quits after early World Cup exit
-
Stokes out for 30 in final Test innings after shock England retirement
-
Venezuela quakes kill 1,400, time running out to find survivors
-
Wolff praises 'cold-blooded' Russell, enjoys Antonelli enthusiasm at Austrian GP
-
Hamilton laments lack of power and poor tyre performance
-
Stokes announces shock England exit as Mitchell bats New Zealand into commanding lead
-
Goals galore at record-breaking World Cup
-
Russell overcomes 'tricky run of form' to revive title bid
-
Augusta Tops Best Gold IRA Companies List By Gold Advisor
-
Europe swelters as heatwave moves east, excess deaths rise
-
They support Argentina at the World Cup, but are not Argentine
-
Raducanu hopes to feature at Wimbledon despite injury woe
-
Iran warns ships not to bypass its chosen Hormuz route
-
Russell holds off Verstappen to win Austrian Grand Prix
-
Serena blasts drug test rules ahead of Wimbledon return
-
England captain Stokes to retire from international cricket
-
Ogier wins Acropolis Rally to close in on Evans
-
South Africa maintain World Cup semi-final hopes with nervy win over Bangladesh
-
South Korea president apologises after World Cup group-stage exit
-
Japan's Ogura wins maiden MotoGP as Bezzecchi crashes in Assen
-
Bergs wins Eastbourne final to clinch first ATP title
Ablexis Reports 33 AlivaMab(R) Mouse-Derived Human Antibodies Now in Clinical Development, Further Validating AlivaMab Mouse Transgenic Platform
80% year-over-year increase in human antibody drug candidates, with the two most advanced now in pivotal Phase 3 trials
SAN DIEGO, CA / ACCESS Newswire / March 4, 2026 / Ablexis, LLC, a biopharmaceutical company advancing human antibody drug discovery through its AlivaMab Mouse platform, today announced that licensees have advanced at least 33 AlivaMab Mouse-derived antibody drug candidates into clinical development. Notably, at least two of these drug candidates have progressed into pivotal phase 3 clinical trials, marking a significant step toward potential regulatory approval and underscoring the growing clinical and commercial momentum of theAlivaMab Mouse platform.
"The patented AlivaMab Mouse is engineered for high efficiency in human antibody drug discovery and development, addressing the risks and limitations inherent to display technologies and other transgenic platforms that make "full human" and "reverse chimeric" antibodies," said Larry Green, Ph.D., Chief Executive Officer of Ablexis. "Leading pharma partners have independently validated that our newer AlivaMab Mouse generations substantially increase hit rates and expand the diversity of unique antibody clonotypes and epitope coverage while retaining inherent drug-like qualities, raising the probability of success for difficult targets and reducing timelines. Crucially, because antibody discovery typically precedes clinical entry by several years, the 33 clinical candidates reported today reflect the productivity of earlier AlivaMab Mouse generations. The continuous improvements we have made mean the clinical pipeline built on today's AlivaMab Mouse technology will be even more robust."
Ablexis offers the AlivaMab Mouse platform to partners for in-house use under flexible financial terms. AlivaMab Biologics provides integrated antibody discovery and engineering services using AlivaMab Mouse on a milestone- and royalty-free basis.
About Ablexis, LLC
Ablexis, LLC develops and licenses AlivaMab Mouse, a patented, next-generation suite of transgenic mice serving as a foundational platform for human antibody drug discovery and development. More than two dozen companies - including 13 of the world's top 25 global pharmaceutical companies - have licensed AlivaMab Mouse for antibody drug discovery. Ablexis' sister company, AlivaMab Biologicsprovides an integrated antibody therapeutic discovery and engineering platform using the AlivaMab Mouse technologies. For more information, visit www.ablexis.com or contact [email protected].
###
Media Contact:
Maya Tanaka
[email protected]
SOURCE: Ablexis, LLC
View the original press release on ACCESS Newswire
N.Walker--AT
